Use of serum fibroblast growth factor 23 vs. plasma B-type natriuretic peptide levels in assessing the pathophysiology of patients with heart failure
Miki Imazu(National Cerebral and Cardiovascular Center), Masafumi Kitakaze(Hanwa Memorial Hospital), Hiroshi Asanuma(Meiji University of Integrative Medicine), Hideaki Kanzaki(National Cerebral and Cardiovascular Center), Naoki Mochizuki(National Cerebral and Cardiovascular Center), Toshihisa Anzai(Hokkaido University), Hiroyuki Takahama(Tohoku University), Makoto Amaki(National Cerebral and Cardiovascular Center), Takuya Hasegawa(National Cerebral and Cardiovascular Center), Takahiro Ohara(Tohoku Medical and Pharmaceutical University), Masanori Asakura(National Cerebral and Cardiovascular Center), Yasuo Sugano(keiyu Hospital)
Cited by 15
Related Papers
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: Metalloproteinase inhibitors as a new therapy
|Nature Medicine|2002|722
Right Ventricular Function in Heart Failure With Preserved Ejection Fraction
|Circulation|2014|456
Cyclic AMP Potentiates Vascular Endothelial Cadherin-Mediated Cell-Cell Contact To Enhance Endothelial Barrier Function through an Epac-Rap1 Signaling Pathway
|Molecular and Cellular Biology|2004|414